Brain

Theralase(R) Technology Effective in Virus Inactivation

TORONTO, ON / ACCESSWIRE / June 4, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage…

7 months ago

Nexalin Technology to Present at the Spring MicroCap Rodeo Conference on June 6th

HOUSTON, TX, June 04, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) announced today…

7 months ago

Indaptus Therapeutics to Present New Positive Data on Decoy20 at Next-Gen Immuno-Oncology Conference

NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc, (Nasdaq: INDP), a clinical stage biotechnology company dedicated to…

7 months ago

Apollomics Announces Vebreltinib Data at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Data from Phase 2 and 2/3 trials demonstrate continued efficacy and safety of vebreltinib for treating different tumor types carrying…

7 months ago

BioVie Announces Formation of Advisory Board for Bezisterim in Long COVID

Scientific Advisory Board to play pivotal role in guiding and accelerating bezisterim long COVID Phase 2b trial supported by an…

7 months ago

Hyperfine, Inc. to Host Analyst and Investor Education Webcast with Clinical and Brain Imaging Experts on June 25, 2024

- Led by Edmond Knopp, MD, VP of Medical Affairs - Welcoming three KOLs to discuss clinical developments in ultra-low-field…

7 months ago

Psirenity Health Adds Key Executive to its Experienced and Innovative Leadership Team

Oakville, Ontario--(Newsfile Corp. - June 3, 2024) - Psirenity Health is incredibly pleased to announce that Mr. Andrew Macdonald has…

7 months ago

CNS Pharmaceuticals Announces Reverse Stock Split

HOUSTON, TX / ACCESSWIRE / June 3, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company…

7 months ago

FDA Provides Feedback and Reaches Consensus on Nexalin’s Design for Planned Anxiety and Insomnia Clinical Studies of its Gen-3 HALO Clarity™ Headset Device

Clinical studies in anxiety and insomnia expected to commence in the third quarter of 2024HOUSTON, TX, June 03, 2024 (GLOBE…

7 months ago